AAS
ONCY

Ameritas Advisory Services’s Oncolytics Biotech ONCY Stock Holding History

Ameritas Advisory Services’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-750
Closed -$580 – 2674
2025
Q2 		$580 Buy
+750
New +$397 ﹤0.01% 2686

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Ameritas Advisory Services's ONCY Position: Q3 2025 in Review

Ameritas Advisory Services sold out of Oncolytics Biotech (ONCY) in Q3 2025, closing a stake of 750 shares — an estimated $580 sold.

Ameritas Advisory Services first reported a position in ONCY in Q2 2025 and held it in 1 quarter. The position peaked at $580 in Q2 2025. 56 funds tracked by Wall St. Rank hold ONCY as of Q3 2025.

  • Ameritas Advisory Services reported no remaining Oncolytics Biotech position as of Q3 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 750 Oncolytics Biotech shares in Q3 2025, an estimated $580.
  • Ameritas Advisory Services first reported a position in Oncolytics Biotech in Q2 2025 and held it in 1 quarter.
  • Ameritas Advisory Services's Oncolytics Biotech position peaked at $580 in Q2 2025.
  • 56 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.